ESMO 2022 | PEACE-1: 8-month PSA determines outcomes in men with mCSPC

Name: PEACE-1: 8-month PSA determines outcomes in men with mCSPC
Uploaded: 2022-09-09T00:00:00Z
Duration: 5 min 27 s

Gwenaëlle Gravis Mescam • 9 Sep 2022

ESMO 2022

Genitourinary Cancer Prostate Cancer Abiraterone Docetaxel Prednisone

PEACE-1

Gwenaëlle Gravis Mescam, MD, Institut Paoli Calmettes, Marseille, France, discusses data concerning the 8-months PSA decline in the Phase III PEACE-1 trial (NCT01957436), which assessed the addition of abiraterone plus prednisone to androgen deprivation therapy (ADT) with or without docetaxel in men with metastatic castration sensitive prostate cancer (mCSPC). The association between the 8-months PSA value and overall survival and radiological progression-free survival (rPFS) was assessed, with the cut-off being 0.2 ng/ml. The 8-months PSA value was determined to be an accurate indicator of survival outcomes in patients, where the triplet therapy provided statistically significant benefit in patients. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.